Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 19, Number 3—March 2013

Research

Treatment Outcomes for Extensively Drug-Resistant Tuberculosis and HIV Co-infection

Max R. O’DonnellComments to Author , Nesri Padayatchi, Charlotte Kvasnovsky, Lise Werner, Iqbal Master, and C. Robert Horsburgh
Author affiliations: Author affiliations: Albert Einstein College of Medicine, Bronx, New York, USA (M.R. O’Donnell); Centre for AIDS Programme of Research in South Africa, Durban, South Africa (M.R. O’Donnell, N. Padayatchi, L. Werner); University of Maryland School of Medicine, Baltimore, Maryland, USA (C. Kvasnovsky); King George V Hospital, Sydenham, South Africa (I. Master); Boston University School of Public Health, Boston, Massachusetts, USA (C.R. Horsburgh, Jr.); Boston University School of Medicine, Boston (C.R. Horsburgh, Jr.)

Main Article

Table 5

Sputum culture conversion at intervals of successful treatment for XDR TB patients, KwaZulu-Natal Province, South Africa*

Time from start of treatment, mo No. cultures converted/total (%) No. cultures converted/ total converted (%) Sensitivity, % Specificity, % Positive predictive value, % Negative predictive value, %
1 4/114 (4) 4/42 (10) 5 98 75 43
2 18/114 (16) 18/42 (43) 19 92 78 42
3 29/114 (25) 29/42 (69) 35 88 79 51
4 33/114 (29) 33/42 (79) 42 88 82 53
6 39/114 (34) 39/42 (93) 51 88 85 57
24 42/114 (37) NA NA NA NA NA

*XDR TB, extensively drug-resistant tuberculosis; NA, not applicable.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO